Market Trends of Global Lyme Disease Diagnostic Industry
This section covers the major market trends shaping the Lyme Disease Diagnostic Market according to our research experts:
Serological Test Segment to Witness Significant Growth Over the Forecast Period in the Lyme Disease Diagnostic Market.
Serological tests are blood tests conducted to detect and measure the concentration of antibodies against bacteria, viruses, and any other foreign particle. Serological tests are widely used for the diagnosis of different types of bacterial, fungal, as well as viral infections. These tests have wide applications in diagnostic laboratories for the detection of infectious diseases, blood group typing, and diagnosis of autoimmune disorders.
The serological test is expected to dominate the segment as this test is highly preferable among all the tests owing to measures the antibodies in the late phase of the illness when both the nucleic acid test and polymerase chain reaction test are negative. These tests are very beneficial in terms of evaluating Lyme disease. Serological tests include ELISA, agglutination, precipitation, and western blot methods used to identify infectious diseases. Moreover, the rising prevalence of Lyme disease and growing demand for diagnostic tests among the targeted patient pool opt for this test and promote the Lyme disease diagnostic market. For instance, in 2021 an article titled 'Recent Progress in Lyme Disease and Remaining Challenges' published in the journal Frontiers reported that Lyme disease (also known as Lyme borreliosis) is the most common vector-borne disease in the United States with an estimated 476,000 cases per year.
Recent technological advancements and growing demand for diagnostic tests among the targeted patient is driving this market segment. In June 2022, Adaptive Biotechnologies Corporation aimed to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease and announced the launch of T-Detect Lyme. The T-Detect test detects an immune response by leveraging the body's unique T-cell response to disease-associated antigens. T-Detect Lyme identifies T cells activated by Borrelia burgdorferi, the bacterium that causes Lyme disease, to help diagnose early Lyme disease.
Thus, due to the above-mentioned aforesaid reasons, the market segment is expected to show significant market growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Lyme disease diagnostic market. This can be attributed to the increasing prevalence of tick-borne diseases and increasing initiatives by government and private institutes for diagnosing Lyme disease in this region. For instance, in 2021 according to the Centers for Disease Control and Prevention (CDC), around 300000 people were diagnosed with Lyme disease every year in North America. Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fuelling the growth of the overall regional market to a large extent.
Sever prominent key market players in the region have expanded their Lyme disease diagnostic portfolios for detecting germs that cause Lyme diseases. For instance, in 2022 T2 Biosystems created T2Lyme Panel Diagnostic technology for detecting germs that cause Lyme diseases. Thus, these technological advancements are propelling the North America Lyme disease diagnostic market ahead. Metabolic biomarkers and biosignatures are being identified and characterized for improved diagnosis. All these technologies contribute to advancing therapeutic development, thus again leading to the advancement of this market in the North American region.
Thus, due to the abovementioned reasons, the market is expected to show significant market growth in the North American region over the forecast period.
